PL3833670T3 - Pochodne 6-(4-amino-3-metylo-2-oksa-8-azaspiro[4.5]dekan-8-ylo)-3-(2,3-dichlorofenylo)-2-metylopirymidyn-4(3h)-onu oraz powiązane związki jako inhibitory ptpn11 (shp2) do leczenia raka - Google Patents
Pochodne 6-(4-amino-3-metylo-2-oksa-8-azaspiro[4.5]dekan-8-ylo)-3-(2,3-dichlorofenylo)-2-metylopirymidyn-4(3h)-onu oraz powiązane związki jako inhibitory ptpn11 (shp2) do leczenia rakaInfo
- Publication number
- PL3833670T3 PL3833670T3 PL19759185.2T PL19759185T PL3833670T3 PL 3833670 T3 PL3833670 T3 PL 3833670T3 PL 19759185 T PL19759185 T PL 19759185T PL 3833670 T3 PL3833670 T3 PL 3833670T3
- Authority
- PL
- Poland
- Prior art keywords
- ptpn11
- shp2
- methylpyrimidin
- decan
- azaspiro
- Prior art date
Links
- WYUIJDCKOPRFJO-UHFFFAOYSA-N 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4-one Chemical class NC1C(OCC11CCN(CC1)C1=CC(N(C(=N1)C)C1=C(C(=CC=C1)Cl)Cl)=O)C WYUIJDCKOPRFJO-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862717588P | 2018-08-10 | 2018-08-10 | |
| US201862773921P | 2018-11-30 | 2018-11-30 | |
| PCT/US2019/045903 WO2020033828A1 (en) | 2018-08-10 | 2019-08-09 | 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3833670T3 true PL3833670T3 (pl) | 2024-08-19 |
Family
ID=67766350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19759185.2T PL3833670T3 (pl) | 2018-08-10 | 2019-08-09 | Pochodne 6-(4-amino-3-metylo-2-oksa-8-azaspiro[4.5]dekan-8-ylo)-3-(2,3-dichlorofenylo)-2-metylopirymidyn-4(3h)-onu oraz powiązane związki jako inhibitory ptpn11 (shp2) do leczenia raka |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US11104675B2 (pl) |
| EP (2) | EP3833670B1 (pl) |
| JP (2) | JP2021534124A (pl) |
| KR (1) | KR102707409B1 (pl) |
| CN (1) | CN112601750B (pl) |
| AU (1) | AU2019319971A1 (pl) |
| BR (1) | BR112021002327A2 (pl) |
| CA (1) | CA3109181A1 (pl) |
| CL (1) | CL2021000355A1 (pl) |
| CO (1) | CO2021003074A2 (pl) |
| CR (1) | CR20210132A (pl) |
| DK (1) | DK3833670T3 (pl) |
| ES (1) | ES2981592T3 (pl) |
| FI (1) | FI3833670T3 (pl) |
| HR (1) | HRP20240861T1 (pl) |
| IL (2) | IL280701B2 (pl) |
| LT (1) | LT3833670T (pl) |
| MX (2) | MX2021001608A (pl) |
| PE (1) | PE20211050A1 (pl) |
| PH (1) | PH12021550268A1 (pl) |
| PL (1) | PL3833670T3 (pl) |
| PT (1) | PT3833670T (pl) |
| RS (1) | RS65728B1 (pl) |
| SG (1) | SG11202100199UA (pl) |
| SI (1) | SI3833670T1 (pl) |
| TW (1) | TWI827646B (pl) |
| UA (1) | UA128559C2 (pl) |
| WO (1) | WO2020033828A1 (pl) |
| ZA (1) | ZA202101449B (pl) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11466017B2 (en) | 2011-03-10 | 2022-10-11 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
| AU2017274199B2 (en) | 2016-05-31 | 2021-09-23 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
| EP3515916B1 (en) | 2016-09-22 | 2023-06-07 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| TWI848901B (zh) | 2016-10-24 | 2024-07-21 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
| EP3630770B1 (en) | 2017-05-26 | 2024-08-28 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
| WO2019067843A1 (en) | 2017-09-29 | 2019-04-04 | Relay Therapeutics, Inc. | PYRAZOLO [3,4-B] PYRAZINE DERIVATIVES AS INHIBITORS OF PHOSPHATASE SHP2 |
| IL301106A (en) | 2018-03-21 | 2023-05-01 | Relay Therapeutics Inc | SHP2 phosphatase inhibitors and methods of using them |
| AU2019263294B2 (en) | 2018-05-02 | 2024-03-21 | Navire Pharma, Inc. | Substituted heterocyclic inhibitors of PTPN11 |
| WO2020033828A1 (en) | 2018-08-10 | 2020-02-13 | Board Of Regents, The University Of Texas System | 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer |
| CA3113234A1 (en) | 2018-09-18 | 2020-03-26 | Nikang Therapeutics, Inc. | Tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors |
| EA202191498A1 (ru) | 2018-11-30 | 2021-08-20 | Мерк Шарп энд Доум Корп. | 9-замещенные производные аминотриазолохиназолина в качестве антагонистов аденозиновых рецепторов, фармацевтические композиции и их применение |
| JP2022511469A (ja) | 2018-11-30 | 2022-01-31 | コメット セラピューティクス インコーポレイテッド | 環状パンテテイン誘導体及びその使用 |
| MA55511A (fr) | 2019-04-02 | 2022-02-09 | Array Biopharma Inc | Inhibiteurs de protéine tyrosine phosphatase |
| CA3127475A1 (en) | 2019-04-08 | 2020-10-15 | Merck Patent Gmbh | Pyrimidinone derivatives as shp2 antagonists |
| WO2021061706A1 (en) | 2019-09-24 | 2021-04-01 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of making and using the same |
| JP2023500328A (ja) | 2019-11-08 | 2023-01-05 | レボリューション メディシンズ インコーポレイテッド | 二環式ヘテロアリール化合物及びその使用 |
| CN115916194A (zh) | 2020-06-18 | 2023-04-04 | 锐新医药公司 | 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法 |
| WO2022060583A1 (en) | 2020-09-03 | 2022-03-24 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| AU2021345111A1 (en) | 2020-09-15 | 2023-04-06 | Revolution Medicines, Inc. | Indole derivatives as Ras inhibitors in the treatment of cancer |
| WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| WO2022235864A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors |
| CN117616031A (zh) | 2021-05-05 | 2024-02-27 | 锐新医药公司 | 用于治疗癌症的ras抑制剂 |
| TW202313041A (zh) | 2021-06-09 | 2023-04-01 | 瑞士商諾華公司 | 包含達拉菲尼、曲美替尼和shp2抑制劑之三重藥物組合 |
| TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途 |
| WO2023031781A1 (en) | 2021-09-01 | 2023-03-09 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
| WO2023056037A1 (en) * | 2021-09-30 | 2023-04-06 | Navire Pharma, Inc. | Combination therapy using substituted pyrimidin-4(3h)-ones and sotorasib |
| JP2024536338A (ja) | 2021-09-30 | 2024-10-04 | ナビール ファーマ，インコーポレイティド | Ｐｔｐｎ１１阻害剤とｅｇｆｒ阻害剤を用いた併用療法 |
| AU2022360835A1 (en) * | 2021-10-06 | 2024-05-16 | Navire Pharma, Inc. | Substituted pyrimidin-4(3h)-ones for use in treating cancer |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| WO2023205794A1 (en) | 2022-04-22 | 2023-10-26 | Bristol-Myers Squibb Company | Combination therapy using a pyrimidone derivative as ptpn11 inhibitor and a pd-1/pd-l1 inhibitor and its use in the treatment of cancer |
| TW202404599A (zh) * | 2022-04-22 | 2024-02-01 | 美商必治妥美雅史谷比公司 | 使用經取代之嘧啶-4(3h)-酮及納武單抗(nivolumab)之組合療法 |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2024206858A1 (en) | 2023-03-30 | 2024-10-03 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| WO2024211663A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007504243A (ja) | 2003-09-03 | 2007-03-01 | ニューロジェン・コーポレーション | ５−アリール−ピラゾロ［４，３−ｄ］ピリミジン類、ピリジン類、ピラジン類及び関連化合物 |
| MXPA06009462A (es) | 2004-02-27 | 2007-03-15 | Hoffmann La Roche | Derivados pirazolo heteroaril fusionados. |
| US7897607B2 (en) | 2004-04-07 | 2011-03-01 | Takeda Pharmaceutical Company Limited | Cyclic compounds |
| JP2008520738A (ja) | 2004-11-22 | 2008-06-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼの阻害剤として有用なピロロピラジンおよびピラゾロピラジン |
| GB0427604D0 (en) | 2004-12-16 | 2005-01-19 | Novartis Ag | Organic compounds |
| GB0506147D0 (en) | 2005-03-24 | 2005-05-04 | Merck Sharp & Dohme | Therapeutic agents |
| WO2008061109A2 (en) | 2006-11-15 | 2008-05-22 | Forest Laboratories Holdings Limited | Indazole derivatives useful as melanin concentrating receptor ligands |
| KR20090110913A (ko) * | 2007-02-15 | 2009-10-23 | 노파르티스 아게 | Ｌｂｈ589와 암을 치료하기 위한 다른 치료제와의 조합물 |
| EP2350020B1 (en) | 2008-10-03 | 2014-08-13 | Merck Sharp & Dohme Corp. | Spiro-imidazolone derivatives as glucagon receptor antagonists |
| JP2010111624A (ja) | 2008-11-06 | 2010-05-20 | Shionogi & Co Ltd | Ｔｔｋ阻害作用を有するインダゾール誘導体 |
| KR20110049217A (ko) | 2009-11-04 | 2011-05-12 | 다우어드밴스드디스플레이머티리얼 유한회사 | 신규한 유기 발광 화합물 및 이를 채용하고 있는 유기 전계 발광 소자 |
| JP2011246389A (ja) | 2010-05-26 | 2011-12-08 | Oncotherapy Science Ltd | Ｔｔｋ阻害作用を有する縮環ピラゾール誘導体 |
| JPWO2012011592A1 (ja) * | 2010-07-23 | 2013-09-09 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| EP2670733B1 (en) | 2011-02-01 | 2019-04-10 | The Board of Trustees of the University of Illionis | N-hydroxybenzamide derivatives as hdac inhibitors and therapeutic methods using the same |
| WO2013052263A2 (en) | 2011-09-16 | 2013-04-11 | Microbiotix, Inc. | Antifungal compounds |
| WO2013040527A1 (en) | 2011-09-16 | 2013-03-21 | Microbiotix, Inc. | Antimicrobial compounds |
| WO2014047662A2 (en) | 2012-09-24 | 2014-03-27 | Whitehead Institute For Biomedical Research | Indazole derivatives and uses thereof |
| CN110423212B (zh) | 2013-04-26 | 2023-05-09 | 美国印第安纳大学研究和技术公司 | Shp2的基于羟基吲哚羧酸的抑制剂 |
| WO2014200682A1 (en) | 2013-05-24 | 2014-12-18 | The Scripps Research Institute | Bidentate-binding modulators of lrrk2 and jnk kinases |
| WO2015099481A1 (ko) | 2013-12-27 | 2015-07-02 | 주식회사 두산 | 유기 전계 발광 소자 |
| CN105899493B (zh) | 2014-01-17 | 2019-03-29 | 诺华股份有限公司 | 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物 |
| ES2699351T3 (es) | 2014-01-17 | 2019-02-08 | Novartis Ag | Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2 |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| KR101998435B1 (ko) | 2014-06-09 | 2019-07-09 | 주식회사 두산 | 유기 전계 발광 소자 |
| US9902719B2 (en) * | 2014-07-03 | 2018-02-27 | Celgene Quanticel Research, Inc. | Inhibitors of lysine specific demethylase-1 |
| KR101708097B1 (ko) | 2014-10-22 | 2017-02-17 | 주식회사 두산 | 유기 전계 발광 소자 |
| EP3273959A1 (en) | 2015-03-25 | 2018-01-31 | Novartis Ag | Pharmaceutical combinations |
| JP6878316B2 (ja) * | 2015-06-19 | 2021-05-26 | ノバルティス アーゲー | Ｓｈｐ２の活性を阻害するための化合物および組成物 |
| WO2016203404A1 (en) | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| JP6718889B2 (ja) | 2015-06-19 | 2020-07-08 | ノバルティス アーゲー | Ｓｈｐ２の活性を阻害するための化合物および組成物 |
| WO2017156397A1 (en) | 2016-03-11 | 2017-09-14 | Board Of Regents, The University Of Texas Sysytem | Heterocyclic inhibitors of ptpn11 |
| CN107286150B (zh) | 2016-04-11 | 2020-07-07 | 中国科学院上海有机化学研究所 | N-杂环类化合物、其中间体、制备方法、药物组合物和应用 |
| AU2017274199B2 (en) | 2016-05-31 | 2021-09-23 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
| MA45189A (fr) | 2016-06-07 | 2019-04-10 | Jacobio Pharmaceuticals Co Ltd | Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2 |
| CA3023216A1 (en) | 2016-06-14 | 2017-12-21 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| JP6916279B2 (ja) | 2016-07-12 | 2021-08-11 | レヴォリューション・メディスンズ，インコーポレイテッド | アロステリックｓｈｐ２阻害剤としての２，５−二置換３−メチルピラジンおよび２，５，６−三置換３−メチルピラジン |
| EP3515916B1 (en) | 2016-09-22 | 2023-06-07 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| TWI848901B (zh) | 2016-10-24 | 2024-07-21 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
| WO2018130928A1 (en) | 2017-01-10 | 2018-07-19 | Novartis Ag | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor |
| EP4230623A3 (en) | 2017-01-23 | 2023-10-11 | Revolution Medicines, Inc. | Pyridine compounds as allosteric shp2 inhibitors |
| WO2018136265A1 (en) | 2017-01-23 | 2018-07-26 | Revolution Medicines, Inc. | Bicyclic compounds as allosteric shp2 inhibitors |
| KR20220113545A (ko) | 2017-03-23 | 2022-08-12 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Shp2 억제제로서 유용한 신규한 헤테로환형 유도체 |
| EP3630770B1 (en) | 2017-05-26 | 2024-08-28 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
| EP3678703A1 (en) | 2017-09-07 | 2020-07-15 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
| CN111201223B (zh) | 2017-09-11 | 2024-07-09 | 克鲁松制药公司 | SHP2的八氢环戊二烯并[c]吡咯别构抑制剂 |
| WO2019067843A1 (en) | 2017-09-29 | 2019-04-04 | Relay Therapeutics, Inc. | PYRAZOLO [3,4-B] PYRAZINE DERIVATIVES AS INHIBITORS OF PHOSPHATASE SHP2 |
| CA3078565A1 (en) | 2017-10-12 | 2019-04-18 | Revolution Medicines, Inc. | Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors |
| EP3724189B1 (en) | 2017-12-15 | 2023-10-04 | Revolution Medicines, Inc. | Polycyclic compounds as allosteric shp2 inhibitors |
| WO2019152454A1 (en) | 2018-01-30 | 2019-08-08 | Research Development Foundation | Shp2 inhibitors and methods of use thereof |
| MA51845A (fr) | 2018-02-13 | 2020-12-23 | Shanghai Blueray Biopharma Co Ltd | Composé cyclique fusionné à une pyrimidine, son procédé de préparation et son application |
| EP3755699A1 (en) | 2018-02-21 | 2020-12-30 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| CA3092011A1 (en) | 2018-03-02 | 2019-09-06 | Otsuka Pharmaceutical Co., Ltd. | Pharmaceutical compounds |
| IL301106A (en) | 2018-03-21 | 2023-05-01 | Relay Therapeutics Inc | SHP2 phosphatase inhibitors and methods of using them |
| CA3097709A1 (en) | 2018-03-21 | 2019-09-26 | Synblia Therapeutics, Inc. | Shp2 inhibitors and uses thereof |
| US20210069188A1 (en) | 2018-03-21 | 2021-03-11 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof |
| WO2019199792A1 (en) | 2018-04-10 | 2019-10-17 | Revolution Medicines, Inc. | Shp2 inhibitor compositions, methods for treating cancer and methods for identifying a subject with shp2 mutations |
| AU2019263294B2 (en) | 2018-05-02 | 2024-03-21 | Navire Pharma, Inc. | Substituted heterocyclic inhibitors of PTPN11 |
| CN115969853A (zh) | 2018-05-09 | 2023-04-18 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
| US20210230300A1 (en) | 2018-06-04 | 2021-07-29 | Bayer Aktiengesellschaft | Inhibitors of shp2 |
| BR112021001292A2 (pt) | 2018-07-24 | 2021-05-11 | Otsuka Pharmaceutical Co., Ltd | compostos heterobicíclicos para inibir a atividade de shp2 |
| TWI825144B (zh) | 2018-08-10 | 2023-12-11 | 美商思達利醫藥公司 | 第二型轉麩醯胺酸酶(tg2)抑制劑 |
| WO2020033828A1 (en) | 2018-08-10 | 2020-02-13 | Board Of Regents, The University Of Texas System | 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer |
| AR117200A1 (es) | 2018-11-30 | 2021-07-21 | Syngenta Participations Ag | Derivados de tiazol microbiocidas |
| EA202191498A1 (ru) | 2018-11-30 | 2021-08-20 | Мерк Шарп энд Доум Корп. | 9-замещенные производные аминотриазолохиназолина в качестве антагонистов аденозиновых рецепторов, фармацевтические композиции и их применение |
| JP2022511469A (ja) | 2018-11-30 | 2022-01-31 | コメット セラピューティクス インコーポレイテッド | 環状パンテテイン誘導体及びその使用 |
| KR20210097154A (ko) | 2018-11-30 | 2021-08-06 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Hiv 요법에 유용한 화합물 |
| AR117183A1 (es) | 2018-11-30 | 2021-07-14 | Syngenta Crop Protection Ag | Derivados de tiazol microbiocidas |
-
2019
- 2019-08-09 WO PCT/US2019/045903 patent/WO2020033828A1/en active Application Filing
- 2019-08-09 MX MX2021001608A patent/MX2021001608A/es unknown
- 2019-08-09 SG SG11202100199UA patent/SG11202100199UA/en unknown
- 2019-08-09 BR BR112021002327-5A patent/BR112021002327A2/pt unknown
- 2019-08-09 SI SI201930743T patent/SI3833670T1/sl unknown
- 2019-08-09 EP EP19759185.2A patent/EP3833670B1/en active Active
- 2019-08-09 PE PE2021000191A patent/PE20211050A1/es unknown
- 2019-08-09 HR HRP20240861TT patent/HRP20240861T1/hr unknown
- 2019-08-09 CR CR20210132A patent/CR20210132A/es unknown
- 2019-08-09 UA UAA202101174A patent/UA128559C2/uk unknown
- 2019-08-09 JP JP2021506929A patent/JP2021534124A/ja not_active Ceased
- 2019-08-09 US US16/536,923 patent/US11104675B2/en active Active
- 2019-08-09 DK DK19759185.2T patent/DK3833670T3/da active
- 2019-08-09 PT PT197591852T patent/PT3833670T/pt unknown
- 2019-08-09 FI FIEP19759185.2T patent/FI3833670T3/fi active
- 2019-08-09 CN CN201980046071.6A patent/CN112601750B/zh active Active
- 2019-08-09 AU AU2019319971A patent/AU2019319971A1/en active Pending
- 2019-08-09 RS RS20240780A patent/RS65728B1/sr unknown
- 2019-08-09 ES ES19759185T patent/ES2981592T3/es active Active
- 2019-08-09 LT LTEPPCT/US2019/045903T patent/LT3833670T/lt unknown
- 2019-08-09 EP EP24161326.4A patent/EP4356973A3/en active Pending
- 2019-08-09 KR KR1020217003134A patent/KR102707409B1/ko active IP Right Grant
- 2019-08-09 IL IL280701A patent/IL280701B2/en unknown
- 2019-08-09 PL PL19759185.2T patent/PL3833670T3/pl unknown
- 2019-08-09 CA CA3109181A patent/CA3109181A1/en active Pending
- 2019-08-09 IL IL307361A patent/IL307361B1/en unknown
- 2019-08-12 TW TW108128631A patent/TWI827646B/zh active
-
2021
- 2021-02-04 PH PH12021550268A patent/PH12021550268A1/en unknown
- 2021-02-09 MX MX2024001249A patent/MX2024001249A/es unknown
- 2021-02-10 CL CL2021000355A patent/CL2021000355A1/es unknown
- 2021-03-03 ZA ZA2021/01449A patent/ZA202101449B/en unknown
- 2021-03-09 CO CONC2021/0003074A patent/CO2021003074A2/es unknown
- 2021-07-20 US US17/380,943 patent/US11945815B2/en active Active
-
2023
- 2023-08-17 JP JP2023132960A patent/JP2023144075A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL280701A (en) | History of 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(3,2-dichlorophenyl)-2-methylpyrimidin-4(H3)-one and compounds related as PTPN11 (SHP2) inhibitors for cancer treatment | |
| PH12018500792A1 (en) | Benzolactam compounds as protein kinase inhibitors | |
| MX2019007643A (es) | Benzoisotiazol, isotiazolo[3,4-b]piridina, quinazolina, ftalazina, pirido[2,3-d]piridazina y derivados de pirido[2,3-d]pirimidina como inhibirores de kras g12c para tratar el cancer de pulmon, pancreatico o colorrectal. | |
| EP4010080C0 (en) | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | |
| MX2020012261A (es) | Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer. | |
| EP3781564C0 (en) | PYRIDAZINE DERIVATIVES FOR THE TREATMENT OF CANCER | |
| EP3489232A3 (en) | Inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| WO2018013867A8 (en) | Inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| JOP20200209A1 (ar) | مثبطات cd73 | |
| MX2023010882A (es) | Compuestos y composiciones para el tratamiento de trastornos hematológicos. | |
| MX2017011206A (es) | Combinacion de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cancer. | |
| SI3724191T1 (sl) | 5-(2-(2,5-difluorofenil)pirolidin-1-IL)-3-(1H-pirazol-1-IL)pirazolo (1,5-A)pirimidinski derivati in povezane spojine kot inhibitorji trk kinaze za zdravljenje raka | |
| SI3880676T1 (sl) | Derivati 2,3-dihidro-1h-pirolo(3,4-c)piridin-1-ona kot zaviralci hpk1 za zdravljenje raka | |
| IL290177A (en) | History of 4,2,1-oxadiazol-5-one for cancer therapy | |
| IL288529A (en) | History of imidazo[2,1-c]pyrimidine as prc2 inhibitors for cancer therapy | |
| SG11202008291XA (en) | 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer | |
| EP3847283A4 (en) | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HER INDUCED CANCERS | |
| EP3838898C0 (en) | ISOINDOLIN-1-ONE DERIVATIVE, PROCESS FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF FOR THE PREVENTION OR TREATMENT OF CANCER | |
| IL284124A (en) | History of quinoline for use in the treatment or prevention of cancer | |
| IL282273A (en) | History of Urea for the treatment and prevention of cancer | |
| IL282692A (en) | Compounds derived from madrasin, a preparation and their uses for the treatment of cancer | |
| ZA202005311B (en) | 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer |